First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.
The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.
A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.